Europeanhhm

Introducing the newly available Labcorp Plasma Focus™ Liquid Biopsy Test

Thursday, June 01, 2023

Labcorp, a global life sciences company listed on the NYSE as LH, has recently unveiled Labcorp Plasma Focus. This innovative liquid biopsy test is designed to assist in the selection of targeted therapies for patients with advanced or metastatic solid tumors. By evaluating circulating cell-free DNA (cfDNA) released by tumor cells, Labcorp Plasma Focus empowers treating oncologists to develop personalized and targeted therapy plans for improved patient care.

Liquid biopsy tests have several advantages, including the use of a standard blood draw, rapid result delivery, and increased accessibility to precision medicine. In conjunction with the launch of Labcorp Plasma Focus, Labcorp has published an analytical validation article that demonstrates the test's accuracy, sensitivity, and specificity in genomic profiling. The article, which has undergone peer review, can be accessed here.

Dr. Prasanth Reddy, Labcorp's Senior Vice President and Global Enterprise Head of Oncology, emphasizes the significance of Labcorp Plasma Focus, stating,The introduction of Labcorp Plasma Focus is a pivotal step in expanding Labcorp's range of precision oncology tests. By using a minimally invasive blood draw, we can identify clinically actionable biomarkers across a range of common cancer types, while minimizing the physical burden on patients. At Labcorp, we are committed to providing vital insights that drive better outcomes at every stage of a patient's journey, and Labcorp Plasma Focus will enhance a physician's ability to develop an individualized care plan.

Labcorp Plasma Focus enables healthcare providers to identify biomarkers associated with targeted therapies earlier and more efficiently. The goal is to improve survival outcomes and reduce disease-related costs. The test analyzes  circulating cell-free DNA (cfDNA) to detect significant genetic changes that can guide therapy selection for various cancer types, including non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma. Collectively, these cancers account for nearly 800,000 newly diagnosed cases and over 230,000 deaths annually in the United States. Labcorp Plasma Focus complements tissue-based genomic testing, particularly in cases where tissue samples are unavailable or inaccessible. The introduction of this test underscores Labcorp's commitment to scientific innovation and improving patient access to precision oncology tests.

Dr. Brian Caveney, Labcorp's Chief Medical and Scientific Officer, highlights the company's dedication to delivering critical insights at every stage of patient care. He states, "Labcorp is focused on delivering vital insights to physicians, patients, cancer care teams, and our biopharma partners. The development and launch of Labcorp Plasma Focus mark a significant milestone in leveraging technology to enable earlier therapy selection, empowering oncologists to better manage patient care.


Source: ir.labcorp.com


 

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024